Cian Healthcare Limited has announced receipt of trading approval from BSE Limited for 2,50,00,000 fully paid-up equity shares, marking a crucial step in the company's restructuring process following the NCLT-approved resolution plan. The trading approval, received on March 30, 2026, enables the company's equity shares to be admitted for trading on BSE Limited effective April 2, 2026.

Share Allocation Structure

The approved equity shares carry a face value of INR 10 each and are distributed across two distinct categories of shareholders as per the resolution plan framework.

Resolution Plan Implementation

The trading approval stems from the Hon'ble National Company Law Tribunal (NCLT) order dated December 18, 2025, which approved the resolution plan submitted by the Successful Resolution Applicant, Mr. Pradeep Kumar Jain, under the Insolvency and Bankruptcy Code, 2016. The public shareholders' allocation of 12,50,000 shares was approved during the Resolution Plan Implementation Committee meeting held on January 23, 2026, while the promoters' allocation of 2,37,50,000 shares received approval in the Board of Directors meeting conducted on March 16, 2026.

Regulatory Compliance Framework

The disclosure has been made in compliance with Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Additionally, the company has adhered to provisions outlined in SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2//3762/2026 dated January 30, 2026, ensuring comprehensive regulatory compliance throughout the process.

Trading Commencement Details

BSE Limited has confirmed that trading members of the Exchange are authorized to trade in the company's securities effective April 2, 2026. The equity shares bear distinctive numbers ranging from 1 to 25000000, providing clear identification for trading purposes. This development represents the culmination of the corporate restructuring process initiated under the insolvency and bankruptcy proceedings.

Corporate Information

Cian Healthcare Limited operates as an ISO 9001:2015 and WHO GMP certified company with its registered office located in Pune, Maharashtra, and corporate office in New Delhi. The company maintains manufacturing facilities in Uttarakhand and continues to focus on pharmaceutical operations while navigating the post-resolution phase of its corporate journey.

Cian Healthcare Limited has received listing approval from BSE Limited for 2,37,50,000 equity shares worth ₹23.75 crores issued to promoters on preferential basis. The company filed a regulatory disclosure on March 21, 2026, confirming receipt of BSE's listing approval letter dated March 20, 2026, following the earlier board-approved equity allotment completed on March 16, 2026.

BSE Listing Approval and Trading Formalities

BSE Limited granted listing approval for 2,37,50,000 fully paid-up equity shares at face value of ₹10 each, bearing distinctive numbers from 1250001 to 2500000. The approval was communicated through reference number LOD/PREF/TS/FIP/4134/2025-26 dated March 20, 2026. The company must now complete requisite trading formalities and credit shares to respective demat accounts of shareholders.

Promoter Shareholding Structure

The preferential allotment establishes a clear promoter structure with three key stakeholders receiving the allocated shares. The distribution maintains the previously announced shareholding pattern with Ananta Medicare Limited emerging as the largest promoter.

The allotment increased the company's equity share capital from ₹1.25 crores to ₹25.00 crores, with the combined promoter group holding 95% of the company's equity.

Regulatory Compliance and Trading Requirements

BSE has specified several compliance requirements before granting trading approval. The company must file confirmation letters from NSDL/CDSL regarding crediting shares to beneficiary accounts and admitting capital to the depository system. Additionally, the company must ensure compliance with Regulation 167 of SEBI (ICDR) Regulations and file shareholding pattern in XBRL mode under Regulation 31(1)(c) of SEBI LODR Regulations, 2015.

NCLT Resolution Plan Background

This development follows the National Company Law Tribunal Mumbai Bench-VI's approval of the resolution plan on December 18, 2025. The plan was submitted by Mr. Pradeep Kumar Jain as the Successful Resolution Applicant under the Insolvency and Bankruptcy Code, 2016. The company had previously received in-principle approval on March 11, 2026, for the preferential issue.

Pradeep Kumar Jain had earlier filed comprehensive SEBI disclosures under Regulation 29(1) and Regulation 10(6) on March 17 and March 18, 2026, respectively, confirming his acquisition of 47,50,000 equity shares worth ₹4,75,00,000 through the preferential allotment.

Company Operations and Market Position

Cian Healthcare Limited operates as an ISO 9001:2015 and WHO GMP certified pharmaceutical company with its registered office in Pune, Maharashtra. The company maintains corporate operations in New Delhi and manufacturing facilities in Haridwar, Uttarakhand. The company trades on BSE Limited under scrip code 542678 with trading symbol CHCL.